Fineline Cube

Follow:
14437 Articles
Shanghai Pharmaceuticals Partners with Organon to Market Women's Health Products in China
CompanyDeals

Shanghai Pharmaceuticals Partners with Organon to Market Women’s Health Products in China

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial
CompanyDrug

HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer Trial

Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis
CompanyDrug

Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis

Shanghai Healthcare Administration Pushes for 11th Round of VBP
Policy / Regulatory

Shanghai Healthcare Administration Pushes for 11th Round of VBP

Vivolight's Multimodal Coronary OCT System Gains FDA Clearance
CompanyMedical Device

Vivolight’s Multimodal Coronary OCT System Gains FDA Clearance

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101
CompanyDrug

Belief BioMed Gains NMPA Clinical Trial Approval for DMD Gene Therapy BBM-D101

Sanofi's Dupixent Approved by FDA for Chronic Spontaneous Urticaria
CompanyDrug

Sanofi’s Dupixent Approved by FDA for Chronic Spontaneous Urticaria

Biogen's High-Dose Spinraza Regimen Accepted for CDE Review in China
CompanyDrug

Biogen’s High-Dose Spinraza Regimen Accepted for CDE Review in China

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies
CompanyDrug

Sichuan Biokin Gains NMPA Approval for Phase II Trials of BL-B01D1 in Combination Therapies

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine
CompanyDrug

Walvax Biotech Gains NMPA Clinical Clearance for 20-Valent Pneumococcal Vaccine

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs
Company

Asieris Pharmaceuticals Reports Strong 2024 Financial Results for Urogenital Cancer Drugs

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development
CompanyDeals

Shandong Lukang Plans Private Placement to Raise RMB1.2 Billion for Drug Development